AzTrials
AzTrials

Chronic Kidney DiseasesNCT03771703

Sex Differences in Chronic Kidney Disease

An observational study of Chronic Kidney Diseases, run by Assoc. Prof. Dr. Manfred Hecking, MD PhD at 1 site in Austria.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study aims to describe sex specific differences of the hemodialysis population in Austria, to quantify sex specific differences in treatment and outcomes in hospitalized patients with chronic kidney disease and to examine decision making by doctors and patients with regards to hemodialysis initiation. Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Chronic Kidney Diseases
How many people
1,100 participants
Where
1 siteAustria
Study dates
2 Dec 2018to 1 Apr 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • Adult, Older adult

Study population: as specified in the detailed study description

Who may be able to join

  • Austrian Dialysis Registry Patient or outpatient
  • Criteria for participation in the survey will be (i) a diagnosis of CKD (eGFR <60 mL/min/1.73 m2) [50% <15]) and (ii) appropriate language skills to fill in a survey.

Who cannot join

  • Not an Austrian Dialysis Registry Patient or not an outpatient

Trial locations and contacts

1 site in 1 country.

Austria1 site
  • Medical University of Vienna

    Vienna, 1090

Other trials in Austria

About this study

Official title: An Exploratory Study in Three Parts to Determine Sex-Specific Differences in Chronic Kidney Disease Recognition, Progression and Treatment

This study aims to describe sex specific differences of the hemodialysis population in Austria, to quantify sex specific differences in treatment and outcomes in hospitalized patients with chronic kidney disease and to examine decision making by doctors and patients with regards to hemodialysis initiation.

To adequately serve the needs of these research questions, the study is divided into 3 parts (sub-studies).

  1. Description and analysis of sex-specific differences in renal replacement therapy in Austria.
  2. Description and analysis of the competing risks of death versus renal replacement therapy initiation in the chronic kidney disease population by sex.
  3. Analysis of sex differences in renal replacement therapy initiation decisions, emphasizing patient perception and socio-economic differences.
Read the detailed description

2.1-A Renal Replacement Therapy: Description and analysis of sex-specific differences in hemodialysis patients and the associated male-to-female mortality in Austria

Hypothesis:

There are sex-specific differences in hemodialysis incidence/prevalence and mortality among hemodialysis patients in Austria. There are differences in male-to-female mortality among hemodialysis patients as compared to the general population in Austria.

Methodology:

Data extraction will be performed from the Austrian Dialysis registry which holds complete longitudinal entries of all Austrian hemodialysis patients since 1970 and contains data of all patients undergoing hemodialysis in Austria since the year 1965.Demographic data, laboratory values, clinical characteristics and hemodialysis specific data will be collected for every patient registered in the Austrian Dialysis registry between 1965 and 2015.Male and female population structure and mortality data of the Austrian general population will be retrieved from the ´Statistik Austria´ registry.Additional data of the Austrian general population will be retrieved from the SYSKID project and electronic medical records retrieved in the course of an epidemiologic study.

Statistics:

Standard descriptive statistics will be used for tabulations of patient characteristics by sex and decade, of the Austrian hemodialysis population versus general population by sex and age group over time. The unadjusted male-to-female mortality rate ratio in the hemodialysis population will be compared with that of the Austrian general population. Adjusted hazard ratios for the male-to-female mortality risk in hemodialysis patients, by region will be performed using Cox regression analysis. Statistical modeling will closely follow a previously published study of hemodialysis data, analyzed by sex and country/region. All obtained p-values will be considered exploratory in nature.

2.1-B Renal Replacement Therapy: Description and analysis of sex-specific differences in transplantation rates in Austria

Hypothesis:

(i) Women in Austria have lower access to transplantation with a deceased donor organ.(ii) Living kidney donor transplantation is not unfair towards women. (iii) Kidney allograft survival is sex-dependent.

Methodology:

Demographic and clinical characteristics, laboratory values, and hemodialysis specific data will be extracted from the Austrian Dialysis and Transplant registry for all patients registered between 1965 and 2018. Data regarding the time intervals between initiation of dialysis, entry to transplantation waiting list, transplantation, potential graft failure and potential death will be retrieved. Further, data regarding sex of donors and recipients will be extracted.

Statistics:

Hypothesis (i), sex differences in the time to waiting-list entry and time on waiting list, male-to-female hazard ratios will be calculated from competing risk Cox proportional hazards models. The models will include age and relevant comorbidities as adjusting covariates and death will be considered as competing event to transplantation.

Hypothesis (ii), a logistic regression model will be fit to explain the probability for a dialysis patient to receive a living-donor kidney transplant by sex and a comprehensive set of further potential explanatory variables. These will include age, comorbidities, serological markers, and marital status.

The model will be used to calculate covariate adjusted male-to-female odds ratios. In case of a "fair" treatment of men and women, the observed adjusted effect of sex is expected to be close to zero whereas inter-individual differences in the probability to receive a living-donor transplant should be explained through individual, none sex-related covariate values.

Hypothesis (iii), Cox proportional hazard models will be applied for the competing events graft failure and death, with sex as main predictor and demographic and clinical data on donor and recipient as covariates. In a second model sex differences regarding a combined endpoint comprising graft failure and death will be studied as sensitivity analysis.

2.2 Description and analysis of the competing risks of death versus renal replacement therapy initiation in the chronic kidney disease population by sex

Hypothesis:

There are sex-specific differences in the competing risks of death versus renal replacement therapy initiation in the chronic kidney disease population.

Methodology:

The principal data source from Europe is the Stockholm CREAtinine Measurements (SCREAM) cohort. In the SCREAM cohort, 1 Million adult individuals residing in the region of Stockholm/Sweden and undergoing one or more routine serum creatinine assessment between 2006 and 2011 were included. This number of individuals corresponds to 66% coverage of the complete population in the region. The advantages of using the SCREAM cohort are (a) universal healthcare access of the included individuals, (b) the fact that all laboratory values of the included individuals are provided through the central repository of laboratory data (no other laboratory values than the included ones have ever been taken), (c) complete coverage on ICD diagnoses (including primary care) and death, (d) availability of socio-economic information. The most complex part of SCREAM, linking the laboratory data to regional healthcare utilization data was solved by involving the administrative health data register of the region, entitled Vårdanalysdatabasen, (i.e. the Stockholm regional healthcare data warehouse). As SCREAM remains without loss to follow-up and is likely one of the largest and most complete healthcare utilization cohorts in Europe, it is an ideally suited database to answer the research questions laid out here above. The research results obtained by the US team from analyzing USRDS datasets (NHANES, Optum, CMS) will complement the analyses in SCREAM and will either be published back-to-back, or within the same publication. Additional data will be retrieved from international databases (e.g. NHANES, USRDS).

In this model the hazard ratios for three possible transitions (RRT, disease progression, death) are estimated separately for each CKD stage. The model will further account for the influence of covariates such as comorbidities and socio-economic factors. In case of time-varying covariates the last observed value will be utilized in each estimation step. To support a causal conclusion of sex-related effects, a matched-pairs analysis will be performed. Pairs of one woman and one man will be formed using nearest neighbour matching based on potentially confounding covariates and stratified Cox models, treating each pair as stratum, will be fit to calculate the cause-specific hazard ratios between men and woman for RRT, disease progression and death. Further, sex differences in disease progression will be analyzed by comparing the average rates of eGFR decline with time and the hazard rates for reaching secondary endpoints such as doubling of serum creatinine and a decline in eGFR of more than 30%. The rates of referral to a nephrologist and the frequencies of CKD related diagnoses (defined by appropriate CKD-10 codes) will be analyzed and contrasted between sexes. As an important side-effect, we will attempt to define criteria for the "predialysis stage" outside of acutely life-threatening conditions such as hyperkalemia and pulmonary congestion. After the transition of subjects into our defined "predialysis stage", RRT or death may be the consequence and the competing risks for either, as a function of time, will also be analyzed separately between men and women, and subsequently compared.

2.3 Analysis of sex differences in RRT initiation decisions, emphasizing patient perception and socio-economic differences

Hypothesis:

There are sex-specific differences in decision-making of doctors and patients with end-stage renal disease with regards to renal replacement therapy initiation.

Methodology:

Qualitative study: Criteria for participation in our study will be (i) a diagnosis of CKD (eGFR <60 mL/min/1.73 m2, while 50% of all interviews will be conducted among patients with eGFR <15 mL/min/1.73 m2) and (ii) appropriate language skills. In order to gain a holistic perspective on the topic and in addition to the interviews with the patients, we will invite a family member and/or caregiver per patient to participate in an additional interview. Furthermore, we will interview two health professionals who are clinical experts in CKD from different professions in each center regarding their perspectives on gender differences in CKD and access to dialysis. Data collection will be undertaken through semi-structured interviewing. The first interview will start with an open question regarding the most important area in daily life that the health condition has affected. Patients will be encouraged to consider not only present experiences, but also prior experiences from their life stories. The subsequent interview questions will be based on the World Health Organization International Classification of Functioning, Disability and Health (http://www.who.int/classifications/icf/en/) and the Canadian Occupational Performance Measure (http://www.thecopm.ca/) to cover comprehensively all areas of functioning in daily life. The semi-structure interview guide will be adapted for the family members, care givers and health professionals. Two interviews will be performed with each participant. The purpose of the second interview is to give the researcher and the interviewee time to reflect about what was said in the previous interviews. Interviews will be digitally tape-recorded and transcribed verbatim. The analysis will be supported by using appropriate software, e.g. NVivo or AtlasTi. In order to ensure accuracy and rigor of the qualitative analysis, all interviews will be performed according to a pre-determined standard procedure. 10-15% of the results of the different steps of the analysis will be reviewed by a senior researcher with extensive prior experience in the field of qualitative research and one patient research partner. Triangulation will be achieved by comparison of the results, especially new and unexpected findings to literature, also in other diseases.

Based on prior work, we are estimating that a total number of 1000 patient questionnaires will yield adequate information. This sample size will be modified, depending on the results of the qualitative study. For the longitudinal follow-up, we assume that we will be able to reach 50% of the baseline patients who will agree to fill in the follow-up questionnaire as well. We are planning to include up to 10 representative Nephrology clinics in Austria. Data of the returned questionnaires will either be entered into an IBM SPSS statistics database or analyzed in R (www.r-project.org). The analysis of the survey will include descriptive statistics for all variables which will be depicted according to their distribution, as well as sub-group analyses for gender/sex-differences with interferential statistical tests depending again on the distribution of each variable. Graphical illustrations will be performed, as needed. For multiple testing, Bonferroni corrections will be applied. Based on the concepts identified in the qualitative analysis, their meaning and their relationship to each other, we will select the dependent and the independent variables and fit a regression model to explore the relationship between the concepts/variables of the survey in qualitative terms

Medical subject headings
Renal Insufficiency, Chronic

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sex-specific mortality among incident patients undergoing hemodialysis

    "Incident" hemodialysis patients are all those who have entered the Dialysis Registry (they will constitute the study population).

    Measured: Through study completion, the expected average follow-up being 4 years.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Dec 2018
  2. Study start2 Dec 2018
  3. Primary completion1 Mar 2024 (estimated)
  4. Study completion1 Apr 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
1,100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03771703
Sponsor's protocol ID
EK Nr. 1363/2016
Status last verified
Oct 2023
First submitted
2 Dec 2018
Last updated
24 Oct 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Chronic Kidney Diseases, run by Assoc. Prof. Dr. Manfred Hecking, MD PhD at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sex-specific mortality among incident patients undergoing hemodialysis (time frame: Through study completion, the expected average follow-up being 4 years.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in